Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06828731 · ClinicalTrials.gov registry record · Phase 1

Evaluation of Empagliflozin vs Standard Care in Veterans With Prediabetes

A Phase 1 study of PreDiabetes, sponsored by Charles George VA Medical Center.

Completed
Registry status
Phase 1
Development phase
60
Enrollment target
1
Study location

NCT06828731 is a Phase 1 study of PreDiabetes that has completed, run by Charles George VA Medical Center. The registered enrollment target is 60 participants, below the 690-participant average among 89 other PreDiabetes trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06828731, a Phase 1 study of PreDiabetes, has completed, sponsored by Charles George VA Medical Center.

COMPLETED
Registry status
Phase 1
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

Prediabetes effects 96 million people 18 years of age or older. It is important to identify treatment options to slow or prevent progression to diabetes. It is also critical to assess the potential of medications like sodium glucose transporter 2 inhibitors to reduce the risk of cardiovascular events and kidney complications, both common and costly complications of diabetes. This is a 12-week, open-label pilot feasibility study assessing the use of empagliflozin in prediabetes.

Conditions Studied

Interventions

  • DRUG Empagliflozin 10mg daily
  • OTHER Lifestyle education

Study Locations (1)

North Carolina

  • Charles George VA Medical Center - Asheville

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2024-12-06
Est. Completion 2025-09-05
Phase Phase 1

Sponsor

Charles George VA Medical Center

1 total trials

What the Registry Record Tells You About NCT06828731

The ClinicalTrials.gov registry entry for NCT06828731 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 690-participant average among 89 other PreDiabetes trials with a reported enrollment target (91% lower). The listed sponsor is Charles George VA Medical Center, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with PreDiabetes appearing as the primary indexed condition, and to 2 interventions - of which Empagliflozin 10mg daily is the first listed.

NCT06828731 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT06828731 about?

NCT06828731 is a clinical study titled "Evaluation of Empagliflozin vs Standard Care in Veterans With Prediabetes". Prediabetes effects 96 million people 18 years of age or older. It is important to identify treatment options to slow or prevent progression to diabetes. It is also critical to assess the potential of medications like sodium glucose transporter 2 inhibitors to reduce the risk of cardiovascular event...

What is the current status of trial NCT06828731?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2024-12-06. Estimated completion is 2025-09-05.

What conditions does trial NCT06828731 study?

This clinical trial studies the following conditions: PreDiabetes.

What interventions are being tested in trial NCT06828731?

The interventions under investigation include: Empagliflozin 10mg daily (DRUG), Lifestyle education (OTHER).

Who is sponsoring clinical trial NCT06828731?

This trial is sponsored by Charles George VA Medical Center, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06828731 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for PreDiabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.